Skip to content
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Endocrinology · Familial Partial Lipodystrophy Type 3

Symptoms & Warning Signs

At a Glance

FPLD3 can cause gradual loss of fat from the limbs, hips, and sometimes face while severe metabolic problems develop quietly. Very high triglycerides, insulin resistance, and diabetes are common; severe abdominal pain with vomiting may signal pancreatitis and needs urgent care.

Living with Familial Partial Lipodystrophy Type 3 (FPLD3) involves managing both visible physical changes and “silent” metabolic challenges. Because the physical signs of FPLD3 can be more subtle than other types of lipodystrophy, the diagnosis is often missed until metabolic symptoms—like very high triglycerides or early-onset diabetes—become severe [1][2].

Physical Changes: The Pattern of Fat Loss

The hallmark of FPLD3 is a specific pattern of lipoatrophy (loss of fat tissue). While you may have a typical amount of fat on your trunk, you may notice a significant lack of fat in other areas [3].

  • Limbs and Hips: Most patients experience a loss of subcutaneous fat (fat just under the skin) in their arms, legs, and hips [3][4]. This can make the muscles and veins in your limbs appear much more prominent or “defined” [5].
  • The Face: Some people with FPLD3 also experience fat loss in the face, which can lead to a more “hollow” or aged appearance [3].
  • Timeline: While these changes typically begin in late adolescence or early adulthood, they are often so gradual that they go unnoticed for years [2]. Not having obvious limb fat loss does not entirely exclude FPLD3 if your metabolic features are severe.

Metabolic Symptoms: The “Silent” Impact

Because your body lacks enough healthy fat storage space under the skin, fat accumulates as ectopic fat in your bloodstream and organs. This leads to a high “metabolic burden” that is often more severe in FPLD3 than in other forms of lipodystrophy [6].

  • Severe Hypertriglyceridemia: Very high levels of triglycerides (fats) in the blood are frequently reported (affecting 78% to 92% of patients in some clinical cohorts) [2][7].
  • Diabetes and Insulin Resistance: High blood sugar and insulin resistance (where your body doesn’t use insulin effectively) are extremely common in reported cases [2][7]. You may notice acanthosis nigricans—dark, velvety patches of skin in folds like the neck or armpits—which is a physical sign of high insulin levels.
  • Liver and Heart Health: Excess fat often builds up in the liver (steatosis), and hypertension is reported in a majority of patients in clinical series [2][7].

Reproductive Health and PCOS-like Features

For women, FPLD3 often involves symptoms that strongly resemble Polycystic Ovary Syndrome (PCOS). This overlap occurs because high insulin levels can trigger the ovaries to produce excess male hormones (androgens) [8]. Common features include:

  • Hirsutism: Excess hair growth on the face or body [8].
  • Irregular Periods: Infrequent or absent menstrual cycles [5].
  • Frequency: Reviews of FPLD3 cohorts have found PCOS-like features in 58% to 75% of women [2][7]. Note that these symptoms should still be evaluated using standard criteria to exclude other endocrine causes.

⚠️ RED FLAGS: When to Seek Emergency Care

The most dangerous acute complication of severe hypertriglyceridemia in FPLD3 is acute pancreatitis—a sudden, severe inflammation of the pancreas [9]. The risk of pancreatitis rises significantly as triglycerides become severely elevated (especially as they approach or exceed 1,000 mg/dL), but it can occur at lower levels, and a high lab result alone does not always mean you must go to the ER [10][11].

Seek emergency medical attention immediately if you experience severe or persistent symptoms, including:

  • Severe Abdominal Pain: Intense, persistent pain in the upper abdomen that may feel like it is radiating to your back [10].
  • Repeated Nausea and Vomiting: Frequent vomiting and an inability to keep fluids down.
  • Fainting, Confusion, or Fever: Feeling faint, confused, feverish, or noticing a rapidly racing pulse alongside abdominal pain.

When to Contact Your Doctor Promptly (Not necessarily an ER visit):

  • Eruptive Xanthomas: Small, yellow-red bumps that appear suddenly on the skin (usually the back, buttocks, or limbs). These indicate severe hypertriglyceridemia and mean you should contact your care team promptly for a lab check and medication review [10].
  • Rapidly Rising Triglycerides: Work with your doctor to create a personalized action plan for what to do when your routine labs show a sudden spike in triglycerides.

(Note: This list is not exhaustive. Always seek care for concerning or rapidly worsening symptoms. Routine metabolic symptoms, such as slightly elevated blood sugar or mild fatigue, are not emergencies but should be discussed with your care team.)

Common questions in this guide

What physical changes are common in FPLD3?
FPLD3 commonly causes gradual loss of the fat under the skin of the arms, legs, and hips, which can make muscles and veins look more prominent. Some people also lose facial fat, but the changes may be subtle and can go unnoticed for years.
Which metabolic problems can FPLD3 cause?
FPLD3 can cause very high triglycerides, insulin resistance, high blood sugar or diabetes, fatty liver, and high blood pressure. These problems may be severe even when changes in body shape are not obvious.
Can FPLD3 cause symptoms that look like PCOS?
Yes. High insulin levels can contribute to excess facial or body hair and irregular or absent periods in women with FPLD3. These symptoms still need an evaluation for PCOS and other hormone-related causes.
What FPLD3 symptoms require emergency care?
Severe or persistent upper-abdominal pain, especially pain that travels to the back, with repeated vomiting, inability to keep fluids down, fainting, confusion, fever, or a racing pulse can signal acute pancreatitis. Seek emergency medical attention when these symptoms are severe, occur together, or are rapidly worsening.
Do eruptive xanthomas mean my triglycerides are dangerously high?
Eruptive xanthomas are sudden yellow-red bumps, often on the back, buttocks, or limbs, and can be a sign of severe high triglycerides. Contact your care team promptly for testing and medication review; the bumps alone do not always mean you need the emergency department.
Can FPLD3 be present without obvious fat loss?
Yes. Fat loss in FPLD3 may develop gradually and be difficult to notice, so the absence of obvious limb changes does not rule it out. Severe high triglycerides, insulin resistance, or early diabetes should be discussed with a clinician familiar with inherited lipodystrophy.
How is metabolic health monitored in FPLD3?
Your care team may monitor fasting triglycerides, blood sugar or the A1c test, liver enzymes, other blood fats, and blood pressure. Your clinician can set a personal triglyceride threshold for calling the office and decide whether a DXA scan or MRI would help assess fat distribution.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on PPARG-related familial partial lipodystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my physical examination, which areas of my body show the most significant fat loss?
  2. 2.How often should my fasting triglycerides be monitored, and what specific number should trigger a call to your office?
  3. 3.Does my current metabolic profile (A1c, liver enzymes, lipids) match the 'typical' pattern seen in FPLD3?
  4. 4.In my case, how much of my reproductive health symptoms (like irregular periods or hirsutism) are likely driven by my PPARG variant?
  5. 5.Given my history, should I have a specialized scan like a DXA or MRI to better understand my fat distribution?

References

References (11)
  1. 1

    Heterozygous pathogenic PPARG variants in patients with severe hypertriglyceridemia.

    Hang S, Wang J, Taboun Z, et al.

    Journal of clinical lipidology 2025; (19(4)):1085-1090 doi:10.1016/j.jacl.2025.05.021.

    PMID: 40615268
  2. 2

    Familial partial lipodystrophy resulting from loss-of-function PPARγ pathogenic variants: phenotypic, clinical, and genetic features.

    Soares RMV, da Silva MA, Campos JTAM, Lima JG

    Frontiers in endocrinology 2024; (15()):1394102 doi:10.3389/fendo.2024.1394102.

    PMID: 39398333
  3. 3

    Case report: two novel PPARG pathogenic variants associated with type 3 familial partial lipodystrophy in Brazil.

    da Silva MA, Soares RMV, de Oliveira Filho AF, et al.

    Diabetology & metabolic syndrome 2024; (16(1)):145 doi:10.1186/s13098-024-01387-9.

    PMID: 38951919
  4. 4

    Case Report: A New Peroxisome Proliferator-Activated Receptor Gamma Mutation Causes Familial Partial Lipodystrophy Type 3 in a Chinese Patient.

    Chen X, Ma Z, Chen P, et al.

    Frontiers in endocrinology 2022; (13()):830708 doi:10.3389/fendo.2022.830708.

    PMID: 35422762
  5. 5

    Familial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor -γ (PPARG) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 Lamin A/C (LMNA) mutations.

    Demir T, Onay H, Savage DB, et al.

    Diabetic medicine : a journal of the British Diabetic Association 2016; (33(10)):1445-50 doi:10.1111/dme.13061.

    PMID: 26756202
  6. 6

    Phenotypic Differences Among Familial Partial Lipodystrophy Due to LMNA or PPARG Variants.

    Vasandani C, Li X, Sekizkardes H, et al.

    Journal of the Endocrine Society 2022; (6(12)):bvac155 doi:10.1210/jendso/bvac155.

    PMID: 36397776
  7. 7

    Perinatal, metabolic, and reproductive features in PPARG-related lipodystrophy.

    Gosseaume C, Fournier T, Jéru I, et al.

    European journal of endocrinology 2023; (188(3)) doi:10.1093/ejendo/lvad023.

    PMID: 36806620
  8. 8

    Familial Partial Lipodystrophy-Literature Review and Report of a Novel Variant in PPARG Expanding the Spectrum of Disease-Causing Alterations in FPLD3.

    Rutkowska L, Salachna D, Lewandowski K, et al.

    Diagnostics (Basel, Switzerland) 2022; (12(5)) doi:10.3390/diagnostics12051122.

    PMID: 35626278
  9. 9

    Genotype - phenotype correlation in an adolescent girl with pathogenic PPARy genetic variation that caused severe hypertriglyceridemia and early onset type 2 diabetes.

    Gutierrez Alvarez A, Yachelevich N, Kohn B, Brar PC

    Annals of pediatric endocrinology & metabolism 2021; (26(4)):284-289 doi:10.6065/apem.2142056.028.

    PMID: 34991302
  10. 10

    The Chylomicronemia Syndrome Is Most Often Multifactorial: A Narrative Review of Causes and Treatment.

    Chait A, Eckel RH

    Annals of internal medicine 2019; (170(9)):626-634 doi:10.7326/M19-0203.

    PMID: 31035285
  11. 11

    Comprehensive analysis of morbidity and mortality patterns in familial partial lipodystrophy patients: insights from a population study.

    Guidorizzi NR, Valerio CM, Viola LF, et al.

    Frontiers in endocrinology 2024; (15()):1359211 doi:10.3389/fendo.2024.1359211.

    PMID: 38887266

This page explains FPLD3 symptoms and warning signs for informational purposes only and does not constitute medical advice. Ask your healthcare team how your triglyceride levels and symptoms should be monitored, and seek urgent care for severe or worsening symptoms.